Why Amarin (AMRN) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Shares of Amarin  (AMRN) plunged 23.76% to $1.38 Friday after the company announced that the FDA denied its appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.

John Jenkins, the head official in the FDA's Office of New Drugs, denied the appeal. This is the third time Amarin has been rejected when appealing for the SPA for Vascepa. Amarin said it is considering its next move.

More than 8.1 million shares had changed hands as of 11:34 a.m., compared to the average volume of 2,348,200.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AMRN Chart AMRN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

More from Markets

Pot Stocks Are Getting Crushed Along With the Rest of the Market

Pot Stocks Are Getting Crushed Along With the Rest of the Market

Nasdaq Drops Further Into Correction Territory While Dow Falls Nearly 400 Points

Nasdaq Drops Further Into Correction Territory While Dow Falls Nearly 400 Points

Splunk Goes Splunk, Salesforce and Twilio Tumble as Cloud Stocks Fall

Splunk Goes Splunk, Salesforce and Twilio Tumble as Cloud Stocks Fall

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Striking Options: Volatility, Nasdaq, & Treasuries

Striking Options: Volatility, Nasdaq, & Treasuries